Clearmind Medicine Commends U.S. Federal Momentum in Psychedelic Therapy Regulation

Clearmind Medicine Inc. (Nasdaq: CMND) issued a press release on July 17, 2026, commending recent federal initiatives and regulatory momentum in the United States aimed at advancing psychedelic-based therapies for mental health and addiction. The company highlighted several key developments, including final FDA guidance on psychedelic clinical investigations, planned public hearings on therapeutic uses, and new collaborative initiatives involving the Department of Health and Human Services (HHS) and the Department of Veterans Affairs (VA). Clearmind is a clinical-stage biotechnology company focused on non-hallucinogenic neuroplastogen-derived treatments. Its lead candidate, CMND-100 (MEAI), is currently in FDA-cleared Phase I/IIa clinical trials for the treatment of Alcohol Use Disorder (AUD) at institutions including Yale University and Johns Hopkins. The filing serves as a corporate update acknowledging a favorable regulatory environment for the company's development pipeline but does not announce new clinical data or specific trial milestones. Clearmind continues to manage a portfolio of nineteen patent families to support its commercialization efforts for psychedelic-based compounds.